Pfizer Inc. (NYSE:PFE) Shares Sold by Lincluden Management Ltd.

Lincluden Management Ltd. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 358,567 shares of the biopharmaceutical company’s stock after selling 20,910 shares during the period. Pfizer accounts for approximately 1.3% of Lincluden Management Ltd.’s portfolio, making the stock its 17th largest position. Lincluden Management Ltd.’s holdings in Pfizer were worth $14,041,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of PFE. Ameriprise Financial Inc. grew its stake in shares of Pfizer by 111.3% during the first quarter. Ameriprise Financial Inc. now owns 17,940,336 shares of the biopharmaceutical company’s stock worth $649,995,000 after purchasing an additional 9,451,863 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in Pfizer by 125.2% in the first quarter. Canada Pension Plan Investment Board now owns 13,765,773 shares of the biopharmaceutical company’s stock valued at $498,734,000 after acquiring an additional 7,654,145 shares during the last quarter. Franklin Resources Inc. lifted its position in Pfizer by 39.6% in the first quarter. Franklin Resources Inc. now owns 26,553,208 shares of the biopharmaceutical company’s stock valued at $962,030,000 after acquiring an additional 7,532,823 shares during the last quarter. Amundi Asset Management US Inc. raised its holdings in shares of Pfizer by 41.5% in the first quarter. Amundi Asset Management US Inc. now owns 14,037,210 shares of the biopharmaceutical company’s stock valued at $508,569,000 after buying an additional 4,114,833 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Pfizer by 4.1% in the first quarter. Geode Capital Management LLC now owns 94,148,117 shares of the biopharmaceutical company’s stock valued at $3,402,339,000 after buying an additional 3,699,308 shares during the last quarter. Hedge funds and other institutional investors own 64.93% of the company’s stock.

A number of brokerages have recently commented on PFE. JPMorgan Chase & Co. upped their target price on shares of Pfizer from $40.00 to $42.00 and gave the company a “neutral” rating in a report on Monday, September 13th. Berenberg Bank reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a report on Tuesday, June 15th. The Goldman Sachs Group set a $48.00 price target on shares of Pfizer in a report on Thursday, July 29th. SVB Leerink increased their price target on shares of Pfizer from $49.00 to $50.00 and gave the stock a “market perform” rating in a report on Monday, September 20th. Finally, Morgan Stanley increased their price target on shares of Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a report on Thursday, July 29th. Eleven analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $42.85.

In other news, SVP Jennifer B. Damico sold 1,661 shares of the firm’s stock in a transaction on Friday, August 13th. The shares were sold at an average price of $48.30, for a total value of $80,226.30. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction on Friday, July 30th. The shares were sold at an average price of $42.86, for a total transaction of $107,150.00. Following the completion of the transaction, the senior vice president now directly owns 11,430 shares in the company, valued at approximately $489,889.80. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.

Shares of PFE stock traded up $0.15 during trading hours on Monday, hitting $44.09. The company’s stock had a trading volume of 373,933 shares, compared to its average volume of 30,754,012. The business has a fifty day moving average of $45.45 and a 200-day moving average of $40.91. The stock has a market cap of $247.20 billion, a price-to-earnings ratio of 18.81, a P/E/G ratio of 1.58 and a beta of 0.74. Pfizer Inc. has a twelve month low of $33.36 and a twelve month high of $51.86. The company has a current ratio of 1.37, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, July 28th. The biopharmaceutical company reported $1.07 EPS for the quarter, beating the consensus estimate of $0.97 by $0.10. The business had revenue of $18.98 billion for the quarter, compared to analyst estimates of $17.54 billion. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. During the same period in the prior year, the business earned $0.78 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 4.12 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Investors of record on Friday, November 5th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 3.54%. The ex-dividend date of this dividend is Thursday, November 4th. Pfizer’s payout ratio is 70.27%.

Pfizer Profile

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Recommended Story: How is the S&P 500 index different from the DJIA?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.